BTG International, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$8.7M
Doctors Paid
2,436
Transactions
5,589
2024 Total
$1.2M
Payment Breakdown by Category
Research$4.4M (50.1%)
Consulting$2.1M (24.5%)
Travel$401,914 (4.6%)
Food & Beverage$187,220 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $4.4M | 95 | 50.1% |
| Consulting Fee | $2.1M | 248 | 24.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 366 | 12.1% |
| Travel and Lodging | $401,914 | 1,272 | 4.6% |
| Education | $219,619 | 305 | 2.5% |
| Food and Beverage | $187,220 | 3,212 | 2.1% |
| Grant | $133,600 | 27 | 1.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $133,593 | 19 | 1.5% |
| Space rental or facility fees (teaching hospital only) | $57,150 | 41 | 0.7% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $21,268 | 4 | 0.2% |
Payments by Type
Research
$4.4M
95 transactions
General
$4.3M
5,494 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Voraxaze Rescue Use Data | $624,792 | 0 | 6 |
| Single system double blinded trial to evaluate the effect of pre-operative treatment with digiFab to prevent post-operative actute kidney injury (AKI) in patients at high risk for AKI ungergoing cardiac graft surgery | $436,693 | 0 | 9 |
| CROFAB | $354,996 | 0 | 13 |
| Characteristics of Patients Presenting with Digoxin Toxicity and Outcomes of Patients Treated with the Digoxin Immune Fab | $304,293 | 0 | 6 |
| VORAXAZE | $273,768 | 0 | 3 |
| DIGIFAB | $209,707 | 0 | 7 |
| Effects of Digifab on renal function perioperatively | $198,193 | 0 | 3 |
| An Open-Label, Multi-Institutional Phase 0 Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | $194,835 | 0 | 2 |
| Pilot Study of glucarpidase in Patients with Central Nervous System Lymphoma | $165,714 | 0 | 2 |
| Preop DigiFab in CABG to reduce ouabain levels and prevent AKI | $146,288 | 0 | 1 |
| LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | $126,058 | 0 | 2 |
| Gerardo IIS #2 | $124,000 | 0 | 2 |
| A Pilot Study of Voraxaze glucarpidase in Patietns with Central Nervous System Lymphoma | $123,114 | 0 | 3 |
| Utilization of Digoxin Immune Fab for Serious and Life-Threatening Digoxin Toxicity | $110,675 | 0 | 4 |
| An Open-Label Pilot Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | $106,285 | 0 | 2 |
| Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI | $102,860 | 0 | 5 |
| An Open-Label, Multi-Institutional Pilot Study to Assess the Use of Glucarpidase in Patients with Osteosarcoma Receiving High-Dose Methotrexate | $101,272 | 0 | 1 |
| Voraxaze Planned Use Research | $98,280 | 0 | 6 |
| Prediction, Early Detection, and Treatment of Methotrexate-associated Acute Kidney Injury | $89,100 | 0 | 1 |
| Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma | $82,738 | 0 | 4 |
| Anti-tumor study of Glucarpidase with MTHFD2 inhibitor against blood cancer xenograft | $79,999 | 0 | 2 |
| An examination of coagulation and inflammatory response of healthy donor whole blood to three North American snake venoms | $64,557 | 0 | 1 |
| Retrospective review of the response to continuous Antivenom (Crofab) in patients of rattlesnake envenoming | $44,550 | 0 | 1 |
| DigiFab CABG-AKI | $43,500 | 0 | 1 |
| Combination Study of Voraxaze with methylene terahydrofolate dehydrogenase 2 inhibition | $37,408 | 0 | 1 |
| UMB - DigiFab Preclinical (Oubain assay) | $28,777 | 0 | 1 |
| Efficacy of Crotalidae Polyvalent Immune Fab (Ovine) Antivenom Versus Placebo Plus Optional Rescue Therapy on Recovery From Copperhead Snake Envenomation | $25,000 | 1 | 1 |
| Retrospective Review of High Dose Methotrexate Regimen in CNS Lymphoma Treatment | $22,793 | 0 | 1 |
| Rechallenge with Methotrexate after Administration of Glucarpidase for Methotrexate-Associated Acute Kidney Injury | $21,157 | 0 | 1 |
| Investigation of the Pathogenesis of Thrombocytopenia in Rattlesnake Envenomation via Analyses of von Willebrand Factor Multimers and ADAMTS13 Activity | $20,981 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Scott Howard, Md, MD | Pediatric Hematology-Oncology | Memphis, TN | $737,164 | $0 |
| William Banner, M.d, M.D | Pediatric Critical Care Medicine | Oklahoma City, OK | $178,554 | $0 |
| Dr. Spencer Greene, M.d, M.D | Emergency Medicine | Kingwood, TX | $163,274 | $0 |
| Charles Pollack, Md, MD | Emergency Medicine | Roswell, GA | $136,500 | $0 |
| Charles Gerardo, M.d, M.D | Emergency Medicine | Durham, NC | $103,258 | $0 |
| Dr. Eric Lavonas, Md, MD | Emergency Medicine | Denver, CO | $82,283 | $0 |
| Anish Ray, Md, MD | Pediatrics | Fort Worth, TX | $78,501 | $0 |
| Thomas Arnold, M.d, M.D | Emergency Medicine | Shreveport, LA | $75,445 | $0 |
| Dr. Jaya Kala, Md, MD | Nephrology | Houston, TX | $70,227 | $0 |
| Zeyad Kanaan, M.d, M.D | Internal Medicine | Santa Rosa, CA | $62,703 | $0 |
| Joseph Steele, M.d, M.D | Diagnostic Radiology | Englewood, CO | $54,816 | $0 |
| Riad Salem, Md, MD | Vascular & Interventional Radiology | Chicago, IL | $49,172 | $0 |
| Timothy Babinchak, Md, MD | Infectious Disease | Phoenixville, PA | $48,750 | $0 |
| Stephen Solomon, Md, MD | Diagnostic Radiology | New York, NY | $42,616 | $0 |
| Dr. Charles Minn, M.d, M.D | Internal Medicine | Tacoma, WA | $39,126 | $0 |
| Richard Dart, Md, MD | Medical Toxicology | Aurora, CO | $36,385 | $0 |
| Lindsey Epperson | Emergency Medicine | Oklahoma City, OK | $35,656 | $0 |
| Dr. Sean Tutton, Md, MD | Vascular & Interventional Radiology | San Diego, CA | $32,705 | $0 |
| Dr. Jason Hack, Md, MD | Emergency Medicine | Greenville, NC | $30,250 | $0 |
| Robert Vogelzang, Md, MD | Diagnostic Radiology | Chicago, IL | $28,667 | $0 |
| Scott Resnick, Md, MD | Vascular & Interventional Radiology | Chicago, IL | $28,667 | $0 |
| Dr. Lauren Schaff, Md, MD | Student in an Organized Health Care Education/Training Program | New York, NY | $26,710 | $0 |
| Dr. Steven Fein, M.d, M.D | Hematology & Oncology | Miami, FL | $23,159 | $0 |
| Dr. Benjamin Abo, Do, DO | General Acute Care Hospital | Gainesville, FL | $21,745 | $0 |
| Gordon Bernard, Md, MD | Pulmonary Disease | Nashville, TN | $20,677 | $0 |
Ad
Top Products
- VORAXAZE $3.6M
- CROFAB $2.4M
Associated Products (8)
- VORAXAZE $3.7M
- CROFAB $2.4M
- DIGIFAB $1.6M
- CroFab $354,568
- CYANOKIT $164,302
- VISTOGARD-4 $25,210
- DIGIFab $24,539
- VISTOGARD-20 $17,990
Payment Categories
- Food & Beverage $187,220
- Consulting $2.1M
- Travel & Lodging $401,914
- Research $4.4M
About BTG International, Inc.
BTG International, Inc. has made $8.7M in payments to 2,436 healthcare providers, recorded across 5,589 transactions in the CMS Open Payments database. In 2024, the company paid $1.2M. The top product by payment volume is VORAXAZE ($3.6M).
Payments were distributed across 114 medical specialties. The top specialty by payment amount is Emergency Medicine ($846,884 to 633 doctors).
Payment categories include: Food & Beverage ($187,220), Consulting ($2.1M), Research ($4.4M), Travel & Lodging ($401,914).
BTG International, Inc. is associated with 8 products in the CMS Open Payments database, including VORAXAZE, CROFAB, and DIGIFAB.